Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Teleflex ( (TFX) ) has provided an update.
Teleflex announced a major leadership transition effective January 7–8, 2026, with long-time Chairman, President and CEO Liam Kelly departing and board member Stuart Randle, a veteran medical device executive with more than 35 years’ industry experience and a Teleflex director since 2009, stepping in as interim president and CEO. Lead independent director Stephen Klasko was appointed independent chair of the board, while the board engaged Spencer Stuart to search for a permanent chief executive, and Randle’s interim role was formalized through a short-term employment letter that includes a substantial monthly stipend and a $1.5 million restricted stock grant; Kelly, subject to executing a release of claims, is eligible for severance and equity vesting under his existing agreements. The leadership reshuffle comes as Teleflex pursues a strategic transformation following the announced sale of its Acute Care, Interventional Urology and OEM businesses to sharpen its focus on core critical care and high-acuity markets, and it coincided with a downgrade to preliminary full-year 2025 revenue expectations to $3.270 billion–$3.278 billion from prior guidance of $3.305 billion–$3.320 billion, reflecting softer demand for intra-aortic balloon pumps and catheters in the U.S. and Asia, OEM order delays and lower volumes in certain portfolio segments, developments that underscore both operational headwinds and the execution risk around its portfolio repositioning for investors and other stakeholders.
The most recent analyst rating on (TFX) stock is a Hold with a $135.00 price target. To see the full list of analyst forecasts on Teleflex stock, see the TFX Stock Forecast page.
Spark’s Take on TFX Stock
According to Spark, TipRanks’ AI Analyst, TFX is a Neutral.
Teleflex’s overall stock score is driven by strong technical indicators and positive corporate events, which are offset by financial performance challenges and valuation concerns. The company’s strategic moves, such as business sales and share repurchases, enhance its growth potential, but profitability issues need to be addressed.
To see Spark’s full report on TFX stock, click here.
More about Teleflex
Teleflex Incorporated is a global provider of medical technologies focused on improving health and quality of life, with a diverse portfolio spanning anesthesia, emergency medicine, interventional cardiology and radiology, surgical, vascular access and urology. The company operates in core critical care and high-acuity hospital markets and owns a suite of established brands, including Arrow, Barrigel, Deknatel, LMA, Pilling, QuikClot, Rüsch, UroLift and Weck.
Average Trading Volume: 641,664
Technical Sentiment Signal: Sell
Current Market Cap: $5.52B
For detailed information about TFX stock, go to TipRanks’ Stock Analysis page.